Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Part of paid clinical trials in Orange, California.

Sponsor
University of California, Irvine
Study ID
NCT04164979
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Gastric Adenocarcinoma
  • GastroEsophageal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.

Key Dates

Start date
Feb 4, 2020
Status verified
Jul 2025
Primary completion
Nov 25, 2023
Completion
May 30, 2026

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib and Pembrolizumab
    Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.

Primary Outcome Measure

Percentage of Participants With Progression-free Survival at 6 Months [ Time Frame: 6 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Chao Family Comprehensive Cancer Center, University of California, IrvineOrangeCalifornia92868-

Related coverage on Hipa.ai

Find similar trials in Orange, CA

By research site
Chao Family Comprehensive Cancer Center, University of California, Irvine· Orange, CA

Related Studies